The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis
- PMID: 34687427
- PMCID: PMC8540870
- DOI: 10.1007/s40120-021-00285-w
The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis
Abstract
Introduction: A greater understanding of the reality of living with myasthenia gravis (MG) may improve management and outcomes for patients. However, there is little published data on the patient perspective of how MG impacts life. Our objective was to reveal the lived experience of MG from the patient perspective.
Methods: This analysis was led by an international Patient Council comprising nine individuals living with MG who serve as local/national patient advocates in seven countries (Europe and the United States). Insights into the lived experience of MG were consolidated from three sources (a qualitative research study of 54 people with MG or their carers from seven countries; a previous Patient Council meeting [September 2019]; and a literature review). Insights were prioritised by the Patient Council, discussed during a virtual workshop (August 2020) and articulated in a series of statements organised into domains. Overarching themes that describe the lived experience of MG were identified by the patient authors.
Results: From 114 patient insights and supporting quotes, the Patient Council defined 44 summary statements organised into nine domains. Five overarching themes were identified that describe the lived experience of MG. These themes include living with fluctuating and unpredictable symptoms; a constant state of adaptation, continual assessment and trade-offs in all aspects of life; treatment inertia, often resulting in under-treatment; a sense of disconnect with healthcare professionals; and feelings of anxiety, frustration, guilt, anger, loneliness and depression.
Conclusion: This patient-driven analysis enriches our understanding of the reality of living with MG from the patient perspective.
Keywords: Lived experience; Myasthenia gravis; Patient perspective; Qualitative.
© 2021. The Author(s).
Figures
Similar articles
-
Evaluation of the quality of patient involvement in a patient-led analysis of the lived experience of a rare disease.Res Involv Engagem. 2023 May 25;9(1):35. doi: 10.1186/s40900-023-00445-2. Res Involv Engagem. 2023. PMID: 37231525 Free PMC article.
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
Design of and Early Insights From a Generalized Myasthenia Gravis Patient Engagement Research Council.Health Sci Rep. 2024 Dec 17;7(12):e70230. doi: 10.1002/hsr2.70230. eCollection 2024 Dec. Health Sci Rep. 2024. PMID: 39698529 Free PMC article.
-
A state-of-the-art review of the experience of care coordination interventions for people living with multimorbidity.J Clin Nurs. 2020 May;29(9-10):1445-1456. doi: 10.1111/jocn.15206. Epub 2020 Feb 27. J Clin Nurs. 2020. PMID: 32043672 Review.
-
A Review of Psychiatric Comorbidity in Myasthenia Gravis.Cureus. 2020 Jul 14;12(7):e9184. doi: 10.7759/cureus.9184. Cureus. 2020. PMID: 32802619 Free PMC article. Review.
Cited by
-
Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries.BMC Neurol. 2024 Oct 12;24(1):385. doi: 10.1186/s12883-024-03869-9. BMC Neurol. 2024. PMID: 39395956 Free PMC article.
-
Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients.Neurol Ther. 2023 Aug;12(4):1081-1101. doi: 10.1007/s40120-023-00474-9. Epub 2023 Apr 6. Neurol Ther. 2023. PMID: 37024731 Free PMC article.
-
New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies.J Clin Med. 2022 Oct 28;11(21):6394. doi: 10.3390/jcm11216394. J Clin Med. 2022. PMID: 36362622 Free PMC article. Review.
-
Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO.Eur J Neurol. 2025 Aug;32(8):e70231. doi: 10.1111/ene.70231. Eur J Neurol. 2025. PMID: 40755069 Free PMC article. Clinical Trial.
-
The best and worst of times in therapy development for myasthenia gravis.Muscle Nerve. 2023 Jan;67(1):12-16. doi: 10.1002/mus.27742. Epub 2022 Nov 12. Muscle Nerve. 2023. PMID: 36321730 Free PMC article.
References
LinkOut - more resources
Full Text Sources